What is Zacks Research’s Forecast for Surmodics Q1 Earnings?

Surmodics, Inc. (NASDAQ:SRDX) – Stock analysts at Zacks Research lowered their Q1 2027 earnings per share estimates for shares of Surmodics in a research note issued to investors on Tuesday, July 1st. Zacks Research analyst D. Dey now forecasts that the company will post earnings of $0.00 per share for the quarter, down from their prior forecast of $0.01. The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics’ FY2027 earnings at $0.28 EPS.

Several other research analysts have also commented on the stock. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a report on Wednesday, April 30th. Lake Street Capital upgraded shares of Surmodics from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a research report on Friday, March 7th.

Surmodics Stock Performance

Shares of SRDX stock opened at $29.99 on Wednesday. The firm has a market capitalization of $428.79 million, a price-to-earnings ratio of -21.57 and a beta of 1.31. The stock has a fifty day moving average of $28.88 and a 200 day moving average of $31.88. Surmodics has a 52 week low of $26.00 and a 52 week high of $42.44. The company has a quick ratio of 3.99, a current ratio of 5.14 and a debt-to-equity ratio of 0.27.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.07). Surmodics had a negative return on equity of 7.10% and a negative net margin of 16.34%. The business had revenue of $28.09 million during the quarter, compared to analysts’ expectations of $32.23 million.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Strs Ohio bought a new stake in shares of Surmodics during the first quarter valued at approximately $122,000. Legal & General Group Plc lifted its position in Surmodics by 34.2% during the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock valued at $137,000 after buying an additional 880 shares during the period. Price T Rowe Associates Inc. MD purchased a new position in Surmodics during the fourth quarter valued at $217,000. AlphaQuest LLC bought a new stake in shares of Surmodics during the 1st quarter valued at $232,000. Finally, Polymer Capital Management US LLC purchased a new stake in shares of Surmodics in the 4th quarter worth about $255,000. Institutional investors own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).